54 New research has shown that postoperative radiotherapy (PORT) can significantly improve overall survival (OS) and disease-free survival (DFS) in patients who have undergone complete resection of thymoma and thymic carcinoma. The findings, based on a meta-analysis of 31 studies involving over 10,000 patients, shed light on the role of PORT in managing these rare cancers and may help guide future treatment strategies. The findings were published in the journal PLOS One. The study compared the outcomes for patients treated with surgery alone versus surgery plus radiotherapy. It found that those receiving PORT experienced notable improvements in both OS and DFS, particularly for those with stage 3-4 thymoma or thymic carcinoma. For patients with stage 2 disease, however, the benefits of PORT remained less clear, suggesting that its role may depend on more specific clinicopathological features of the tumour. For stage 3-4 thymoma and thymic carcinoma, the evidence suggests that PORT should be considered as part of standard treatment following complete surgical resection. In these advanced cases, the addition of radiotherapy improved OS by approximately 27% and DFS by about 38% compared to surgery alone. This big benefit makes PORT a good choice for people with more aggressive thymic epithelial tumours that could spread to other parts of the body. Modern radiotherapy methods, like three-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT), also seem to play a big role in the better results seen. Studies published after 2015, when these advanced techniques became more common, reported better survival rates than earlier studies that relied more heavily on two-dimensional radiation therapy (2D-RT). This highlights the importance of using updated radiotherapy technologies for optimising treatment outcomes in these patients. While the benefits of PORT are well-supported for stage 3-4 disease, the results for stage 2 thymoma are less consistent. The study’s subgroup analysis did not show a significant survival benefit for patients with stage 2 disease. This inconsistency may be due to the diverse nature of stage 2 thymomas, which can range from relatively indolent tumours to those with more aggressive characteristics. The researchers think that PORT might still be useful for some patients in stage 2, like those whose histological subtypes are more aggressive or who have a lot of capsular invasion. However, more large-scale clinical trials are required to validate these hypotheses and provide a clearer understanding of when PORT is beneficial in earlier-stage disease. The study’s findings emphasise the importance of personalised treatment planning for patients with thymic epithelial tumours. The decision to use PORT should consider the tumour’s stage, histological subtype, and the availability of modern radiotherapy techniques. For advanced-stage thymoma and thymic carcinoma, the evidence supports PORT as an effective way to improve survival outcomes, while its use in stage 2 requires careful evaluation on a case-by-case basis. Given the rarity of thymic epithelial tumours, it is unlikely that large-scale randomised controlled trials will be conducted soon. However, ongoing observational studies and meta-analyses, such as the one reported here, play a crucial role in advancing the understanding of how best to treat these challenging cancers. Clinicians should remain attentive to new evidence as it emerges, particularly regarding the use of advanced radiotherapy technologies, to continue improving outcomes for patients with thymic malignancies.